Pyrotinib Maleate
Phase 3Small molecule
AstraZenecaPyrotinib Maleate is one of 130 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
4
Indications
17
Total Trials
6
Active Trials
129
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Pyrotinib Maleate
AstraZenecaPhase 3
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Acupan
YYonsei University
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer9 trials
Show 6 more trials
Interaction2 trials
Brain Metastases1 trial
3 more indications
Non-Small Cell Lung Cancer1 trial
A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
Unknown status·—··NCT05411276·15 enrolled
Patients With Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pyrotinib Maleate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company